The aim of this study was to compare blood and plasma viscosities, as well as the hematocrit/blood viscosity ratio (HVR), between trained and sedentary SCT carriers. Thirty African male SCT carriers from the city of Dakar (Senegal) participated in the study: one group composed of 15 trained SCT carriers (TSCTc) and one group composed of 15 sedentary individuals (SSCTc). Blood was sampled in resting condition and blood and plasma viscosities were measured using a cone-plate viscometer. After the determination of hematocrit by microcentrifugation, HVR was determined for each subject. Blood and plasma viscosities, as well as hematocrit, were significantly reduced in TSCTc compared to SSCTc. As a consequence, HRV was greater in TSCTc. These findings provide evidence that SCT carriers should be encouraged to practice regular physical activity to limit the cardiovascular strain usually caused by their blood hyperviscosity.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.3233/CH-141852 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Effects of SCT genetic polymorphisms on methotrexate concentrations and toxicities in Chinese children with acute lymphoblastic leukemia.
Leuk Lymphoma
January 2025
Department of Pharmacy, Beijing Shijitan Hospital, Capital Medical University, Beijing, China.
Solute carrier (SLC) transporters play a crucial role in facilitating the cellular uptake of various anticancer drugs, such as methotrexate (MTX). This study aimed to analyze the impact of nonsynonymous single nucleotide polymorphisms (SNPs) in , , and on MTX exposure, toxicities, and prognosis in 148 patients with acute lymphoblastic leukemia (ALL). The rs7311358 polymorphism was significantly associated with the median dose-normalized MTX concentrations at 24 h ( < .
View Article and Find Full Text PDFCirculating biomarkers associated with pediatric sickle cell disease.
Front Mol Biosci
December 2024
Department of Microbiology, Biochemistry and Immunology, Morehouse School of Medicine, Atlanta, GA, United States.
Article Synopsis
- Sickle cell disease (SCD) is a genetic disorder caused by a mutation in the HBB gene, resulting in abnormal hemoglobin S that deforms red blood cells, leading to severe health complications such as pain, anemia, and organ damage.
- The disease is prevalent, especially in sub-Saharan Africa, where over 7.5 million people are affected, often facing underdiagnosis and poor management, particularly in children.
- This study in Ghana aims to identify specific circulating biomarkers in pediatric SCD patients that could help predict disease outcomes and improve patient care by assessing various serum markers associated with inflammation and neuronal injury.
Variability in Notification of Positive Newborn Screening Results for Sickle Cell Trait Across the United States.
Adv Hematol
December 2024
Division of Hematology, Department of Medicine, Johns Hopkins University, Baltimore, Maryland, USA.
Universal in the United States (US) since 2006, newborn screening (NBS) programs for sickle cell disease (SCD) allow for early identification of the disease and, as an unintentional byproduct, identification of sickle cell trait (SCT). Unlike other carrier states, SCT is highly prevalent and is found in nearly 3 million Americans, which results in important reproductive implications. Currently, all NBS programs in the US are responsible for their own policies regarding SCT notification, and little is known about how SCT notification practices are performed and how these practices vary across NBS programs.
View Article and Find Full Text PDFWhy and how citrate may sensitize malignant tumors to immunotherapy.
Drug Resist Updat
January 2025
Institut Cochin, INSERM U1016, CNRS UMR8104, Université Paris Cité, Paris 75014, France. Electronic address:
Article Synopsis
- Immunotherapy, particularly when combined with chemotherapy, has shown limited effectiveness against solid tumors due to factors like cancer cells promoting immune cell exhaustion through nutrient diversion in the tumor microenvironment (TME).
- The authors suggest using high doses of sodium citrate (SCT) alongside immune checkpoint inhibitors (ICIs) to inhibit cancer cell metabolism and enhance anti-tumor immune responses, as preclinical studies indicate SCT can reduce cancer growth and improve chemotherapy outcomes.
- SCT works by increasing available glucose for immune cells and lowering lactic acid levels in the TME, which may enhance T cell activity and repolarize macrophages, indicating its potential to significantly boost the effectiveness of current immunotherapies in clinical settings.
Smart Cancer-Targeting and Super-Sensitive Sensing of Eu/Tb-Induced Hyaluronan Characteristic Nano-Micelles with Effective Drug Loading and Release.
Molecules
October 2024
Institute of Hybrid Materials, National Center of International Joint Research for Hybrid Materials Technology, National Base of International Science & Technology Cooperation on Hybrid Materials, Qingdao University, 308 Ningxia Road, Qingdao 266071, China.
To avoid the critical problems of effective drugs not being carried to their targeted cancers and their quantity and location not being sensed in situ, this work presents a completely new innovative strategy to achieve both smart cancer targeting (SCT) and super-sensitive sensing (SSS), where one drug carrier works for effective drug loading and release. Herein, malignant melanoma treatment is used as an example of reliable detection and effective therapy. We report two characteristic dumbbell-like nano-micelles and spherical-like nano-micelles of hyaluronan induced by the Eu/Tb complexes for effective drug loading and release, respectively.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!